Senseonics Holdings, Inc.

Equities

SENS

US81727U1051

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:00 2024-05-03 pm EDT			5-day change	1st Jan Change
0.5049 ^USD	-2.55%		+21.46%	-11.44%

Apr. 30	Senseonics Holdings, Inc. Announces Eversense CGM System Receives iCGM Designation by the U.S. Food and Drug Administration	CI
Mar. 25	Senseonics Holdings, Inc. Announces Board Changes	CI

Senseonics Holdings, Inc. Provides Revenue Guidance for the First Half of 2024

February 29, 2024 at 04:13 pm EST

Senseonics Holdings, Inc. provided revenue guidance for the first half of 2024. For the period, the company expects first half of 2024 global net revenue to be nearly $10 million, representing growth of approximately 16% compared to the first half of 2023.

Latest news about Senseonics Holdings, Inc.

Senseonics Holdings, Inc. Announces Eversense CGM System Receives iCGM Designation by the U.S. Food and Drug Administration	Apr. 30	CI
Senseonics Holdings, Inc. Announces Board Changes	Mar. 25	CI
Transcript : Senseonics Holdings, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Senseonics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Senseonics Holdings, Inc. Provides Revenue Guidance for the First Half of 2024	Feb. 29	CI
Earnings Flash (SENS) SENSEONICS HOLDINGS Posts Q4 Revenue $8M, vs. Street Est of $7.6M	Feb. 29	MT
Senseonics Q4 Revenue Guidance Tops Consensus	Jan. 02	MT
Earnings Flash (SENS) SENSEONICS HOLDINGS Reports Q3 Revenue $6.1M, vs. Street Est of $5.5M	Nov. 09	MT
Senseonics Holdings, Inc. Provides Earnings Guidance for the Year 2023	Nov. 09	CI
Transcript : Senseonics Holdings, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Senseonics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Senseonics Holdings, Inc. Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study	23-09-26	CI
Senseonics Holdings, Inc.(NYSEAM:SENS) dropped from S&P Healthcare Equipment Select Industry Index	23-09-18	CI
Senseonics Holdings, Inc. Enters into $50 Million Loan Facility with Hercules Capital, Inc	23-09-11	CI
Senseonics Holdings, Inc. announced that it expects to receive $50 million in funding	23-09-07	CI
Insider Buy: Senseonics Holdings	23-08-31	MT
HC Wainwright Adjusts Senseonics Price Target to $2 From $3, Maintains Buy Rating	23-08-15	MT
Senseonics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Transcript : Senseonics Holdings, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2023	23-08-10	CI
Earnings Flash (SENS) SENSEONICS HOLDINGS Reports Q2 Revenue $4.1M, vs. Street Est of $4.49M	23-08-10	MT
Jefferies Starts Senseonics Holdings at Underperform With $0.50 Price Target	23-07-19	MT
Sensonics Holdings, Inc. Announces New Clinical Data Demonstrating the Safety and Accuracy of Eversense Through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions	23-06-26	CI
Senseonics Holdings, Inc.(NYSEAM:SENS) dropped from Russell 3000 Index	23-06-23	CI
Senseonics Holdings, Inc.(NYSEAM:SENS) dropped from Russell 3000E Growth Index	23-06-23	CI

Chart Senseonics Holdings, Inc.

Duration

Period

More charts

Company Profile

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user's smartphone. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. Its CGM system continually and accurately measures a person's glucose levels for up to six months.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-13 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Senseonics Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.5049 USD

Average target price

1.633 USD

Spread / Average Target

+223.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
SENSEONICS HOLDINGS, INC.	-11.44%	268M
ABBOTT LABORATORIES	-3.79%	184B
MEDTRONIC PLC	-0.84%	108B
BECTON, DICKINSON AND COMPANY	-3.75%	67.82B
DEXCOM, INC.	+3.45%	51.05B
CENCORA, INC.	+9.04%	44.67B
HOYA CORPORATION	+3.40%	41.78B
METTLER-TOLEDO INTERNATIONAL, INC.	+3.21%	26.78B
WEST PHARMACEUTICAL SERVICES, INC.	+3.66%	26.59B
TERUMO CORPORATION	+15.23%	25.86B

Other Medical Equipment, Supplies & Distribution